Brief description of study

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus
epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants
with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell
death ligand 1 (PD-L1).